SCHEMBL6464186

SCHEMBL6464186

CCc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1cccnc1

nearest known ligand 0.81

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
AR P10275 7/20 0.81
CYP11B2 P19099 4/20 0.42
GRIA2 P42262 2/20 0.42
GRIA4 P48058 2/20 0.42
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP11B1 P15538 1/20 0.38
PDE9A O76083 1/20 0.38
PDE1C Q14123 1/20 0.38
DYRK1A Q13627 1/20 0.38
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6469609 0.91 AR (0.70) ARCYP11B2GRIA2GRIA4ALDH1A1
SCHEMBL6465272 0.90 AR (1.00) ARCYP11B2ALDH1A1HSD17B10CYP11B1
SCHEMBL6464840 0.85 AR (0.78) ARCYP11B2CYP11B1PDE9APDE1C
SCHEMBL6466418 0.84 AR (0.80) ARCYP11B2ALDH1A1HSD17B10CYP11B1
SCHEMBL6464828 0.82 AR (0.77) ARCYP11B2ALDH1A1HSD17B10CYP11B1
SCHEMBL6465363 0.80 AR (0.76) ARCYP11B2ALDH1A1HSD17B10CYP11B1
SCHEMBL6468892 0.78 AR (0.77) ARCYP11B2ALDH1A1TSHRMAPK1
SCHEMBL6889299 0.77 AR (0.72) ARCYP11B2TSHR
SCHEMBL6469303 0.76 AR (0.67) ARTSHR
SCHEMBL6464451 0.76 AR (0.80) ARCYP11B2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050101657-A1 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101657-A1 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative SHBG, PRLHR, FSHR AR 6/4885CYP11B2 151/4885GRIA2 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.